Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
PMV Pharmaceuticals (PMVP) will present updated pivotal Phase 2 PYNNACLE results for rezatapopt at ENA 2026 on November 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals (PMVP) will present updated pivotal Phase 2 PYNNACLE results for rezatapopt at ENA 2026 on November 20, 2026.
The late-breaking oral presentation will include updated data from all trial cohorts, highlighting efficacy across tumor types and in the ovarian cancer primary analysis population. It will address efficacy, molecular activity and safety in TP53 Y220C-positive advanced solid tumors. Alison M. Schram of Memorial Sloan Kettering Cancer Center will present abstract 12LBA at 15:00 CET during Plenary Session 7 at the International Barcelona Convention Center. No numerical efficacy or safety results are provided in this announcement.
Details
Market move: PMVP -3.99% in the Nov 4 session. Phase 2 clinical data
On Nov 4, the day this news came out, PMVP closed 3.99% below the previous close. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner recorded 5 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 4 session.
Key Terms
fast track designation regulatory
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Late-breaking oral presentation to highlight efficacy data across tumor types and in the ovarian cancer primary analysis population
PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt will be featured in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The presentation will include updated data from all PYNNACLE trial cohorts.
| Presentation details: | |
| Title: | Efficacy, molecular activity and safety from the pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a p53 reactivator, in TP53 Y220C-positive advanced solid tumors |
| Session Date and Time: | November 20, 2026 at 15:00 CET |
| Session Title: | Plenary Session 7 - Proffered Papers: Novel Agents and Targets |
| Presenter: | Alison M. Schram, M.D., Memorial Sloan Kettering Cancer Center |
| Abstract Number: | 12LBA |
| Location: | International Barcelona Convention Center, Rooms 111 and 112 |
About Rezatapopt
Rezatapopt (PC14586) is a first-in-class, small molecule, p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein, restoring the wild-type tumor-suppressor function. The U.S. Food and Drug Administration granted Fast Track designation to rezatapopt for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation and Orphan Drug Designation for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
About the PYNNACLE Clinical Trial
The ongoing Phase 1/2 PYNNACLE clinical trial is evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation. The primary objective of the Phase 1 portion of the clinical trial was to determine the maximum tolerated dose and recommended Phase 2 dose (RP2D) of rezatapopt when administered orally to patients. Safety, tolerability, pharmacokinetics, and effects on biomarkers were also assessed. The Phase 2 portion is a registrational, single arm, expansion basket clinical trial comprising five cohorts (ovarian, lung, breast, and endometrial cancers, and other solid tumors) with the primary objective of evaluating the efficacy of rezatapopt at the RP2D in patients with TP53 Y220C advanced solid tumors, conducted across approximately 70 sites.
For more information about the Phase 1/2 PYNNACLE clinical trial, refer to www.clinicaltrials.gov (NCT trial identifier NCT04585750).
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s future plans or expectations for rezatapopt, including our ability to obtain approval as a treatment option as a monotherapy, and expectations regarding timing, enrollment status and success of the Phase 2 portion of the current clinical trial for rezatapopt. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities, including the successful filing of NDAs, and planned clinical trials, the Company’s ability to execute on its strategy and operate as a clinical stage company, the potential for clinical trials of rezatapopt or any future clinical trials of other product candidates to differ from preclinical, preliminary or expected results, maintenance by the Company of ODD status and related benefits for rezatapopt, the Company’s ability to fund operations, and the impact that a global pandemic, other public health emergencies or geopolitical tensions or conflicts may have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2026, and its other filings filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
investors@pmvpharma.com
Media Contact:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com
